Development of a disease activity score based on judgment in clinical practice by rheumatologists.
about
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficaciousDAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single componentsPatient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes.Power Doppler sonography in the assessment of synovial tissue of the knee joint in rheumatoid arthritis: a preliminary experience.Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis.Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.The experience of foot problems and decisions to access foot care in patients with rheumatoid arthritis: a qualitative study.Sex differences in rheumatoid arthritis: more than meets the eye..Validation of Leiden Score in Predicting Progression of Rheumatoid Arthritis in Undifferentiated Arthritis in Indian Population.The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study.What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core setSeven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.Time to achieve remission determines time to be in remission.The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study.Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndromeTreating rheumatoid arthritis to target: recommendations of an international task force.Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patientsFactors predicting the outcome of customised foot orthoses in patients with rheumatoid arthritis: a prospective cohort study.Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28Outcome measures in rheumatoid arthritis randomised trials over the last 50 years.Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.Physical activity measured by the SenseWear Armband in women with rheumatoid arthritis.Serum procalcitonin for differentiating bacterial infection from disease flares in patients with autoimmune diseases.Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis.Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density.Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography.Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis.Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.
P2860
Q24795061-1B5FD64D-D207-47BD-BFAB-61ECB9CBFDBBQ24812386-D5BA7C05-4DC5-4259-B203-A9F6480C41A7Q28343376-D7110F26-6D20-4FC4-AAF2-1C42828F52B9Q30494910-30399EC6-8489-489A-9A6E-6EE7187015A9Q30500520-C24514BA-ACD7-47C6-BB33-931508ACEC12Q30631701-63179CAE-62A8-4791-B810-F39F5167EE00Q30812918-5A3FBEFA-5398-4AC2-9E4D-F04C240604DDQ30836343-2DA1458B-7C31-4CF5-A17A-D04B37CEF8F3Q33424033-76DF206E-5EA6-4E1D-B481-3440F4D98753Q33604889-1F9380E8-4297-4C32-9B22-E0D05F7C8D1CQ33918359-120F462F-3393-488F-955E-D7465CE9510DQ33918845-8E5BDA73-98F9-4101-831A-CD985927BB5EQ34027422-9EA916EA-0463-496F-89BE-45C812C30815Q34027517-322A4E0F-4FFC-4BC5-BAFE-8CAEBC57C033Q34027521-BA0E964E-89F5-4F18-9722-D7E148CA7A05Q34047753-F498DE6C-BD0D-45EF-B3FF-E5FBDA92F893Q34117422-7FADF11E-E874-4642-8F15-1088A984C702Q34462557-508C5EC3-08EC-49DD-B13E-571952F68ACCQ34618811-3B5DE18D-D971-43B1-9596-4CC55A5218B0Q34633421-BA20FB32-C071-4C75-B35A-8A37D83B8804Q34654104-5F56B344-8F73-4CBE-9DF9-52895156CE6AQ34896439-8ADFC26D-3290-4203-A739-051C7EA1937BQ34897125-0D9C0766-BE4F-4C1B-A814-93BB642E57F1Q35011229-7D260C56-FE27-40BD-A3AA-8380A81EF447Q35133638-185527E7-B237-42D5-919F-66F97D4EDB41Q35204815-FB3F4613-1D26-4AE8-BAD5-D82FCA550879Q35211925-823CD75A-832A-4686-AE23-BA50AFE9E0B3Q35249630-63447E93-9430-44A1-8FAC-574E1E0572CFQ35553389-95A3E396-B59E-4C9E-8F16-1A950242F34FQ35553602-EE9E718B-ABC2-49FE-BC61-39769A8E7411Q35553970-986FDA0B-30FA-4E06-A110-87FDAE77C4F5Q35554180-1E66BF57-C514-4D6F-AF4C-6BB662EC2FF6Q35554567-AADE661C-057E-4663-B1D3-23E08C07BF60Q35554765-ECB218DF-9AFC-4EA4-BBB1-E72ABB80FAE5Q35554892-413321A8-C363-4E82-9756-698614DF1490Q35555131-627E51C6-F149-4BCE-AC63-6BFE571C11A4Q35555277-258A7D41-AA28-418E-8A25-A6D1FABC8D66Q35555743-43DC79AE-4ACC-4050-8795-E2D798EB2F93Q35557840-5BF7551F-9C5F-41A2-9DC0-255075129CAFQ35579347-318E703B-6807-424A-BA98-CEEAB0219F21
P2860
Development of a disease activity score based on judgment in clinical practice by rheumatologists.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Development of a disease activ ...... l practice by rheumatologists.
@en
Development of a disease activ ...... l practice by rheumatologists.
@nl
type
label
Development of a disease activ ...... l practice by rheumatologists.
@en
Development of a disease activ ...... l practice by rheumatologists.
@nl
prefLabel
Development of a disease activ ...... l practice by rheumatologists.
@en
Development of a disease activ ...... l practice by rheumatologists.
@nl
P2093
P1476
Development of a disease activ ...... al practice by rheumatologists
@en
P2093
van 't Hof M
van Riel PL
van de Putte LB
van der Heijde DM
P304
P407
P577
1993-03-01T00:00:00Z